Ann: CEO Presentation to AGM, page-7

Highlights .... AGM


We have been awarded orphan drug designations for two indications by the FDA.

FAK plays an important role in cancer and a number of fibrotic diseases. .... as we know

Amplia is presented with a wealth of commercial opportunities .... Awesome so much potential to accomodate other avenues

If anything as a company we are a little bit spoilt for choice so we have established a very clear framework on how we can maximise the value of these opportunities.  .... Nice


Our focusing is likely to be towards licensing Partnering or co development arrangements. ..... and again more opportunities

We’ve welcomed two new institutional investors  into our register with platinum investment holdings now holding 16% and blue flag taking a 7%  stake in the company.

The market is starting to pay a lot more attention to Amplia ... Thats not Difficult to see

We are now on the cusp of dosing the first patient in our first clinical trail AMP 945
It’s also worth noting as of  from this week we commenced a selection for the first volunteers in the clinical study’s. .... This is a terrific milestone to achieve

Because this is a study in healthy volunteers we do not expect the ongoing coronavirus to impact the recruitment. We will keep shareholders informed of our progress ..... Excellent

The other main area of our focus beyond stage one Is in Fibrosis diseases
We are particularly interested in pulmonary fibrosis.

While for many fibrosis diseases there are drugs available. In many cases these drugs do not work very well or nave marginal safety profiles.

FAK is known to play and important roll in regulating fibrosis and the data that we have
from our experiments conducted so far, indicate that AMP945 could be effective in both treating and preventing pulmonary fibrosis.
Subject to the results of the phase one trial this is one of the indications that we plan to take AMP945 into more advanced clinical testing.

And it’s certainly an area where the pharmaceutical companies are actively looking to acquire drugs.

The next 12 to 18 months are going to be a very exciting time to be an Amplia shareholder



As said ... ATX could be one of the stocks of the year.

.